Tempest Therapeutics Inc
tempesttx.comWhat Do They Do?
Develops cell therapies and small-molecule drug candidates for blood cancers, solid tumors and immune-related conditions.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In…View ↗
Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications.…View ↗
Our cell therapy programs expand our oncology pipeline with a portfolio of next-generation CAR-T product candidates designed to potentially…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$5.2MView ↗
- ▼ −33% (Loss)
- vs −$7.9M in Q2 FY2025
-
Aug 24, 2026
Nicholas Rossettos was appointed chief financial officer after Justin Trojanowski resigned
Sources
8-K, filed Aug 24, 2026
On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his positions…View ↗
Added cell therapies
The earlier report focused on oral small-molecule cancer drugs and preclinical research; the latest report also describes cell therapies for cancer and immune-related conditions.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 30, 2026We are a clinical-stage oncology company focused on leveraging our deep scientific understanding of cancer biology and medicinal chemistry…View ↗
Who Do They Compete With?
Competes with Ono, Adlai Nortye, Merck, Roche, Exelixis, AstraZeneca, Johnson & Johnson, Bristol Meyers Squibb, Gilead Sciences, Arcellx, Legend Biotech, Allogene, and Cellectis
10-K for FY2025, filed Mar 30, 2026If our current or any future product candidates are approved for the treatment of cancer, they may compete with existing therapies as well…View ↗
Loading...
